<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000046736"><TermName>di-dgA-RFB4</TermName><TermDefinition><DefinitionText>An anticancer drug that is a combination of a monoclonal antibody (RFB4) and an immunotoxin (dgA).</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><SpanishTermName>di-dgA-RFB4</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento contra el cáncer que es una combinación de un anticuerpo monoclonal (RFB4) con una inmunotoxina (dgA).</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateLastModified>2005-03-02</DateLastModified></GlossaryTerm>
